Can Fatty Liver Disease Lead to Liver Cancer?

Fatty liver disease can increase the risk of liver cancer when persistent inflammation leads to advanced fibrosis or cirrhosis, although most people with the condition do not develop cancer. The risk is influenced by liver scarring, diabetes, excess weight, alcohol use and chronic hepatitis B or C. Assessing fibrosis, managing metabolic health, and undergoing appropriate surveillance can help reduce complications and support earlier detection.

Yes, fatty liver disease can increase the risk of liver cancer, particularly when fat accumulation leads to persistent inflammation, advanced liver scarring, or cirrhosis. However, most people with fatty liver disease do not develop cancer, and the risk varies considerably depending on the degree of liver damage and the presence of conditions such as type 2 diabetes, obesity, and chronic viral hepatitis.

Understanding the relationship between fatty liver disease and liver cancer is important because both conditions may progress without obvious symptoms.

Key Takeaways

Fatty liver disease does not inevitably progress to liver cancer, but the risk rises when ongoing liver injury causes advanced fibrosis or cirrhosis.

The current term "metabolic dysfunction-associated steatotic liver disease," or MASLD, describes fatty liver associated with metabolic risk factors such as excess body weight, type 2 diabetes, and abnormal cholesterol levels.

Hepatocellular carcinoma can occasionally develop in people with MASLD who do not have cirrhosis, although the individual risk is substantially higher when advanced scarring is present.

Normal liver enzyme results do not reliably exclude significant fibrosis, so risk assessment may require blood-based fibrosis scores, imaging, or specialised liver stiffness measurements.

Reducing body weight where appropriate, controlling diabetes and cholesterol, exercising regularly, and limiting alcohol can help slow or reverse earlier liver damage and may reduce future complications.

What Is Fatty Liver Disease?

Fatty liver disease occurs when excess fat accumulates within liver cells. A small amount of liver fat may cause little immediate injury, but persistent fat accumulation can make the liver more vulnerable to inflammation, oxidative stress, and scarring.

The terminology used for fatty liver disease has changed. What was previously called non-alcoholic fatty liver disease, or NAFLD, is now commonly known as metabolic dysfunction-associated steatotic liver disease, or MASLD.

MASLD is diagnosed when fat is present in the liver together with at least one cardiometabolic risk factor, such as:

• Excess body weight or an increased waist circumference
• Type 2 diabetes or impaired glucose regulation
• High blood pressure
• Raised triglyceride levels
• Low levels of protective high-density lipoprotein cholesterol

The newer name reflects the close relationship between liver fat and metabolic health. It also avoids defining the condition only by the absence of significant alcohol consumption.

Some people have liver injury related to both metabolic dysfunction and alcohol. This may be classified separately because the combination can accelerate liver damage. It is therefore important for patients to give their doctor an accurate account of their alcohol intake, even when metabolic risk factors such as obesity or diabetes are also present — as both causes may need to be addressed in treatment.

How Can Fatty Liver Disease Lead to Liver Cancer?

Fat accumulation alone is only the starting point of a more complex biological process. Liver cancer risk becomes more concerning when fat accumulation contributes to repeated cell injury, inflammation, and tissue repair over a prolonged period.

Fat accumulates inside liver cells

The liver helps process fats, sugars, and other nutrients. When more fats builds up in the liver than it can handle, triglycerides accumulate inside liver cells called hepatocytes.

This stage is known as steatosis. Some people remain at this stage without developing severe liver injury. Others progress because of a combination of metabolic stress, genetics, diet, gut-derived signals, and other health conditions.

Inflammation and cell injury develop

A more active form of the disease is called metabolic dysfunction-associated steatohepatitis, or MASH. It was previously known as non-alcoholic steatohepatitis, or NASH.

In MASH, liver fat is accompanied by inflammation and hepatocyte injury. Damaged cells release signals that attract immune cells and activate the liver’s repair response.

The liver has a strong ability to regenerate. However, when injury and repair occur repeatedly, this otherwise protective process can contribute to disease. Cells must divide more frequently to replace damaged tissue, creating more opportunities for DNA-copying errors and abnormal cellular changes.

Fibrous scar tissue begins to form

Persistent inflammation activates hepatic stellate cells, which produce collagen and other components of scar tissue. This process is known as fibrosis.

Fibrosis can begin around individual liver cells and blood vessels before spreading into wider bands. Doctors commonly describe fibrosis in stages, from little or no scarring to advanced fibrosis.

Early fibrosis may improve if the underlying cause is controlled. As scarring becomes more extensive, complete reversal becomes more difficult, although slowing or partially improving the disease may still be possible.

Cirrhosis changes the liver environment

Cirrhosis is the most advanced stage of liver scarring. Bands of fibrous tissue divide the liver into abnormal regenerative nodules and distort its normal blood supply and structure.

This creates an environment in which liver cancer is more likely to develop. Several processes may contribute:

• Chronic inflammation continues to damage cellular DNA.
• Repeated cell regeneration increases the opportunity for mutations.
• Oxidative stress damages proteins, cell membranes, and genetic material.
• Scar tissue changes communication between liver cells.
• Immune surveillance may become less effective.
• Abnormal growth signals can allow altered cells to survive and expand.

Over time, a population of abnormal hepatocytes may acquire enough molecular changes to grow uncontrollably and form hepatocellular carcinoma, or HCC, the most common form of primary liver cancer.

From Fatty Liver to Liver Cancer: What Changes at Each Stage?

Progression is not inevitable or identical for every person. The table below shows how liver health and cancer risk may change across the disease spectrum.

The speed of progression varies. Some people have stable steatosis for years, while others develop fibrosis more quickly. A single ultrasound showing fatty liver cannot predict which course a person will follow.

Can Liver Cancer Develop Without Cirrhosis?

Yes. MASLD-related hepatocellular carcinoma can develop in a liver that has not reached cirrhosis. This distinguishes it from some other chronic liver diseases in which most cancers occur after cirrhosis has developed.

Researchers are still investigating why this happens. Possible contributors include metabolic abnormalities, insulin resistance, chronic low-grade inflammation, altered immune responses, and direct effects of excess fat on liver cells.

However, this point needs to be kept in proportion. Fatty liver is common, while liver cancer remains much less common. The individual risk of HCC in people with MASLD but without advanced fibrosis is generally too low to justify routine cancer surveillance for everyone with fatty liver.

Current professional guidance strongly supports HCC surveillance for people with cirrhosis who are suitable for cancer treatment. Guidance differs on surveillance for advanced fibrosis without cirrhosis, so the decision may depend on an individual assessment.

Which Factors Raise Liver Cancer Risk in Someone with Fatty Liver?

The stage of fibrosis is one of the most important predictors, but it is not the only consideration. Risk can be influenced by several factors that act together.

Type 2 diabetes and poor glucose control

Type 2 diabetes is closely associated with MASLD, fibrosis progression, and HCC. Insulin resistance can promote fat production in the liver and contribute to inflammatory and growth-signalling pathways.

Good diabetes management is important even when liver enzymes are normal. Treatment should address blood glucose alongside blood pressure, cholesterol, kidney health, and cardiovascular risk.

Excess weight, particularly around the waist

Abdominal fat is not merely a passive store of energy. It actively releases fatty acids and other substances that can drive insulin resistance and inflammation, both of which contribute to liver injury.

Body mass index can be useful, but it does not show where fat is stored. Waist circumference can provide additional information about central adiposity. This is especially relevant in Asian populations, where metabolic risk may develop at a lower body mass index than expected.

Advanced fibrosis or cirrhosis

Cancer risk rises substantially as liver scarring progresses. Identifying fibrosis is therefore more useful than simply confirming that fat is present.

A person with advanced fibrosis may feel well and have only mild blood test abnormalities. This is why doctors may use additional methods to estimate scarring.

Alcohol consumption

Alcohol and metabolic fatty liver can coexist. Together, they may cause more liver injury than either factor alone.

People with fatty liver should discuss alcohol intake openly with their doctor. The safest limit is not necessarily the same for everyone, particularly when advanced fibrosis, cirrhosis, or another liver disease is present.

Chronic hepatitis B or C

Singapore and the wider Asian region have a significant burden of chronic hepatitis B. A person may also have viral hepatitis alongside fatty liver disease, so both conditions should be considered during liver risk assessment. In a 10-year Singapore study of 673 patients with chronic hepatitis B, the cumulative incidence of hepatocellular carcinoma was 7.8% overall and 29.7% among those with cirrhosis. Another large cohort study found that 9.5% of chronic hepatitis B patients who developed hepatocellular carcinoma had no evidence of cirrhosis at diagnosis. Testing, monitoring, and antiviral treatment where clinically indicated can reduce complications, although ongoing surveillance may still be necessary.

Age, sex and genetic susceptibility

Risk tends to rise with age and may be higher in men. Genetic differences can also influence how readily liver fat leads to inflammation, fibrosis, or cancer.

Genetic testing is not routinely required for everyone with fatty liver. Clinical decisions are usually guided by the overall pattern of liver disease, family history, metabolic health, and non-invasive fibrosis assessment.

Why Normal Liver Enzymes May Not Tell the Whole Story

Alanine aminotransferase, or ALT, and aspartate aminotransferase, or AST, are commonly measured liver enzymes. Elevated results may suggest liver injury, but normal results do not prove that the liver is free from inflammation or fibrosis.

Liver enzymes can fluctuate, and some people with advanced fatty liver disease have results within the laboratory reference range. Conversely, an elevated ALT does not reveal the cause or stage of disease by itself.

Doctors may combine clinical information with:

• Platelet count
• AST and ALT results
• Age
• Diabetes status
• Abdominal ultrasound findings
• Non-invasive scores such as FIB-4
• Transient elastography, which estimates liver stiffness
• Magnetic resonance-based techniques in selected cases
• Liver biopsy when the diagnosis or disease stage remains uncertain

Does Everyone with Fatty Liver Need Liver Cancer Screening?

No. Routine liver cancer surveillance is not recommended solely because fat has been seen on an ultrasound.

Surveillance is generally intended for people whose underlying liver condition places them at a high risk of HCC and who would be able to receive treatment if a tumour were found. People with cirrhosis commonly fall within this group.

HCC surveillance often involves an ultrasound examination every six months, sometimes together with an alpha-fetoprotein, or AFP, blood test. The exact approach should be determined by the treating team. Ultrasound quality can be reduced in some people with obesity or marked liver changes, so alternative imaging may be considered when the liver cannot be assessed adequately.

Surveillance is different from a one-off diagnostic scan. Repeating the assessment at the recommended interval matters because a tumour may develop between examinations.

A person with fatty liver should ask the doctor:

• Do I have evidence of fibrosis or cirrhosis?
• What is my FIB-4 or other fibrosis assessment?
• Do I need transient elastography or specialist evaluation?
• Should I be tested for hepatitis B and hepatitis C?
• Am I in a group that requires regular HCC surveillance?
• How often should my liver condition be reviewed?

What Signs Require Medical Assessment?

Fatty liver disease, advanced fibrosis, and early HCC can all be silent. Waiting for symptoms is therefore not an effective monitoring strategy for someone already known to have advanced liver disease.

Medical assessment is important if a person develops:

• Persistent discomfort in the upper-right abdomen
• Unexplained loss of weight or appetite
• Increasing abdominal swelling
• Yellowing of the skin or eyes
• Dark urine or pale stools
• New swelling in the legs
• Vomiting blood or passing black stools
• Increasing drowsiness, confusion or difficulty concentrating

Some of these features may result from advanced liver disease rather than cancer itself. Both possibilities require prompt evaluation.

Vomiting blood, black stools, marked confusion, or rapidly worsening abdominal swelling may indicate a serious liver complication and warrant urgent medical attention.

Can Reducing Fatty Liver Lower Liver Cancer Risk?

Yes. Preventing or slowing fibrosis is one of the most practical ways to reduce future liver complications. No lifestyle change can guarantee that liver cancer will not occur, but earlier-stage fatty liver disease may improve when its metabolic drivers are addressed.

Achieve gradual, sustainable weight reduction

For people who are above their healthy weight, losing weight can reduce liver fat. Greater weight reduction may also improve inflammation and fibrosis in some individuals.

The aim should be gradual and medically appropriate. Crash diets and unregulated slimming products can create additional health risks. A doctor or dietitian can help set a suitable target based on body composition, medical conditions, and nutritional needs.

Combine aerobic and resistance activity

Exercise can reduce liver fat even when the change on the weighing scale is modest. A sustainable routine may include brisk walking, cycling, or swimming together with resistance training.

Activity should increase gradually, particularly for people who have been sedentary or have cardiovascular, joint, or mobility concerns.

Improve overall dietary habits

A liver-supportive diet prioritises vegetables, fruit, wholegrains, pulses, fish, and appropriate portions of lean protein. It also limits sugar-sweetened drinks, frequent refined carbohydrates, and excess saturated fat.

There is no need to purchase a special liver detox product. The liver already performs detoxification, and supplements marketed for “cleansing” can sometimes cause liver injury.

Manage related medical conditions

Control of diabetes, high blood pressure, and abnormal cholesterol is part of managing MASLD. Prescribed medicines should not be stopped because of assumptions that all medication damages the liver. Treatment decisions should be made with the doctor managing the condition.

Reduce alcohol intake and quit smoking

Alcohol advice should be individualised according to the degree of liver damage. People with cirrhosis or significant fibrosis may be advised to avoid alcohol entirely.

Stopping smoking supports overall cancer and cardiovascular risk reduction. It also reduces an additional risk factor that can compound the health burden of metabolic disease.

Understanding Fatty Liver Disease and Liver Cancer Supports Earlier Action

The connection between fatty liver disease and liver cancer is not a direct or inevitable progression. The greatest concern arises when metabolic liver disease leads to ongoing inflammation, advanced fibrosis, and cirrhosis. Cancer can occasionally develop without cirrhosis, but this does not mean every person with fatty liver needs repeated cancer scans.

The most useful next step after a fatty liver finding is to establish the condition of the liver beneath the fat. Fibrosis assessment, management of metabolic risk factors, and appropriate surveillance for those at higher risk can help prevent serious disease from going unnoticed.

If you have been told that you have fatty liver disease, speak with your doctor about your fibrosis risk and whether further liver assessment is needed. If an abnormal liver lesion or liver cancer has been identified, our multidisciplinary teams at NCCS & SGH assess both the tumour and the underlying liver before recommending care. This combined assessment helps us determine the most appropriate liver cancer treatment for each patient.

Frequently Asked Questions

1. Can a person who is not overweight develop fatty liver disease?
   Yes. MASLD can occur in people whose body mass index is within the normal range. This is sometimes called lean MASLD. Visceral fat, genetics, diet, muscle mass, and conditions such as diabetes can influence risk even when a person does not appear overweight.
   
   
2. Is fatty liver disease contagious?
   No. Fatty liver disease cannot be passed from one person to another. However, infections such as hepatitis B and hepatitis C can cause separate forms of chronic liver disease and may coexist with fatty liver.
   
   
3. Is a liver cyst caused by fatty liver disease?
   Simple liver cysts are fluid-filled structures and are usually unrelated to fatty liver disease. Most are benign and require no treatment, although their appearance, size, and associated symptoms may determine whether further evaluation is needed.
   
   
4. Can children and teenagers develop fatty liver disease?
   Yes. Fatty liver disease can occur in children and adolescents, particularly in association with obesity, insulin resistance, and type 2 diabetes. Assessment and weight management in younger people should be supervised by appropriately trained healthcare professionals to protect growth and nutrition.
   
   
5. Do liver detox teas remove fat from the liver?
   No detox tea has been proven to remove liver fat or prevent liver cancer. Some herbal and slimming products can cause drug interactions or liver injury. A person with abnormal liver tests or known liver disease should discuss supplements and traditional medicines with a doctor before taking them.